GKIM
AMRX icon

GW&K Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

GW&K Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-81
Closed – – 468
2022
Q4 		$0 Buy
+81
New +$182 ﹤0.01% 454
2019
Q4 		– Sell
-387
Closed -$1K – 377
2019
Q3 		$1K Buy
+387
New +$1.35K ﹤0.01% 367
2019
Q2 		– Sell
-1,805,274
Closed -$25.6M – 338
2019
Q1 		$25.6M Sell
1,805,274
-13,363
-0.7% -$177K 0.41% 99
2018
Q4 		$24.6M Sell
1,818,637
-231,128
-11% -$4.16M 0.49% 83
2018
Q3 		$45.5M Buy
2,049,765
+92,859
+5% +$1.95M 0.73% 30
2018
Q2 		$32.1M Buy
+1,956,906
New +$34.3M 0.53% 62

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

GW&K Investment Management's AMRX Position: Q1 2023 in Review

GW&K Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2023, closing a stake of 81 shares.

GW&K Investment Management first reported a position in AMRX in Q2 2018 and held it in 6 quarters. The position peaked at $45.5M in Q3 2018. 144 funds tracked by Wall St. Rank hold AMRX as of Q1 2023.

  • GW&K Investment Management reported no remaining Amneal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • GW&K Investment Management sold 81 Amneal Pharmaceuticals shares in Q1 2023.
  • GW&K Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • GW&K Investment Management's Amneal Pharmaceuticals position peaked at $45.5M in Q3 2018.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2023.

Based on GW&K Investment Management's 13F filing for Q1 2023, filed 9 May 2023.